The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance insights from the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 27, Issue 9 I, 2007, Pages 1306-1312

  Pakyz, Amy L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antibiograms; M39 A guideline; Susceptibility reporting; Susceptibility testing

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLINICAL PRACTICE; PRACTICE GUIDELINE; SHORT SURVEY; TREATMENT PLANNING; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYSICIAN'S PRACTICE PATTERNS; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 34548317159     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9.1306     Document Type: Short Survey

References (26)

1. Lacy MK, Klutman NE, Horvat RT, Zapantis A. Antibiograms: new NCCLS guidelines, development and clinical application. Hosp Pharm 2004;39:542-53.
2. Zapantis A, Lacy MK, Horvat RT, et al. Nationwide antibiogram analysis using NCCLS M39-A guidelines. J Clin Microbiol 2005;43:2629-34.
3. Interagency Task Force on Antimicrobial Resistance. A public health action plan to combat antimicrobial resistance. Part I. Domestic issues. Atlanta 2001:1-43. Available from http://www.cdc.gov/drugresistance/actionplan/ index.htm.
4. Siegel JD, Rhinehart E, Jackson M, Chiarello L, for the Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. Available from http://www.cdc.gov/ncidod/ dhqp/pdf/ar/mdroGuideline2006.pdf. Accessed February 25, 2007.
5. MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005;11:1197-204.
6. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435-40.
7. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497-503.
8. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
9. Lesch C, Itokazu GS, Danziger LH, Weinstein RA. Multihospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001;41:149-54.
10. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-8.
11. Horvat RT, Klutman NE, Lacy MK, Grauer D, Wilson, M. Effect of duplicate isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus on antibiogram data. J Clin Microbiol 2003;41:4611-16.
12. Wilkinson ST, Lacy MK, Horvat RT, Barnes BJ, Grauer DW, Couldry R. Impact of NCCLS M39-A guideline recommendations for duplicate isolate removal on Pseudomonas aeruginosa antibiogram data: a four-year analysis. Presented at the annual meeting of the American College of Clinical Pharmacy, San Francisco, CA, October 23-26, 2005.
13. White RL, Friedrich LV, Burgess DS, Brown EW, Scott LE. Effect of removal of duplicate isolates on cumulative susceptibility reports. Diagn Microbiol Infect Dis 2001;39:251-6.
14. Shannon KP, French GL. Antibiotic resistance: effect of different criteria for classifying isolates as duplicates on apparent resistance frequencies. J Antimicrob Chemother 2002;49:201-4.
15. Magee JT, for the Welsh Antibiotic Study Group. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J Antimicrob Chemother 2004;54:155-62.
16. Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
17. National Committee for Clinical Laboratory Standards. Analysis and presentation of cumulative antimicrobial susceptibility test data. Approved standard M39-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
18. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative antimicrobial susceptibility test data: approved guideline, 2nd edition. CLSI document M39-A2. Reston, VA: Clinical and Laboratory Standards Institute, 2005.
19. Lautenbach E, Nachamkin I. Analysis and presentation of cumulative antimicrobial susceptibility data (antibiograms): substantial variability across medical centers in the United States. Infect Control Hosp Epidemiol 2006;27:409-12.
20. Ernst EJ, Diekema DJ, BootsMiller BJ, et al. Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data? Diagn Microbiol Infect Dis 2004;49:141-5.
21. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006;130:787-93.
22. Mizuta M, Linkin DR, Nachamkin I, et al. Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a combination antibiogram. Infect Control Hosp Epidemiol 2006;27:413-15.
23. White RL, Friedrich LV, Mihm LB, Bosso JA. Assessment of the relationship between antimicrobial usage and susceptibility: difference between the hospital and specific patient-care areas. Clin Infect Dis 2000;31:16-23.
24. Bosso JA, Mauldin PD, Steed LL. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms. Ann Pharmacother 2006;40:1946-9.
25. Bantar C, Alcazar G, Franco D, et al. Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections? J Antimicrob Chemother 2007;59:140-3.
26. Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JE Jr, for the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001;33:324-30.